{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:54:27Z","timestamp":1784166867559,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.medcli.2025.107076","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:03:27Z","timestamp":1750838607000},"page":"107076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Los an\u00e1logos de la PTH\/PTHrP como tratamiento osteoanab\u00f3lico de los pacientes con osteoporosis"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8839-6430","authenticated-orcid":false,"given":"Enrique","family":"Casado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9498-5979","authenticated-orcid":false,"given":"Guillermo","family":"Mart\u00ednez-D\u00edaz-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-5795","authenticated-orcid":false,"given":"Jos\u00e9 Ramon","family":"Caeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107076_bib0280","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","year":"1993","journal-title":"Am J Med."},{"key":"10.1016\/j.medcli.2025.107076_bib0285","first-page":"105","article-title":"The epidemiology of osteoporosis","volume":"133","author":"Clynes","year":"2020","journal-title":"Br Med Bull."},{"key":"10.1016\/j.medcli.2025.107076_bib0290","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","article-title":"SCOPE 2021: A new scorecard for osteoporosis in Europe","volume":"16","author":"Kanis","year":"2021","journal-title":"Arch Osteoporos."},{"key":"10.1016\/j.medcli.2025.107076_bib0295","doi-asserted-by":"crossref","first-page":"101754","DOI":"10.1016\/j.berh.2022.101754","article-title":"Osteoporosis in 2022: Care gaps to screening and personalised medicine","volume":"36","author":"Curtis","year":"2022","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"10.1016\/j.medcli.2025.107076_bib0300","first-page":"373","article-title":"Gu\u00eda SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualizaci\u00f3n [SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update]","volume":"59","author":"Etxebarria-Foronda","year":"2015","journal-title":"Rev Esp Cir Ortop Traumatol."},{"key":"10.1016\/j.medcli.2025.107076_bib0305","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.reuma.2018.09.004","article-title":"Recommendations by the Spanish Society of Rheumatology on Osteoporosis","volume":"15","author":"Naranjo Hern\u00e1ndez","year":"2019","journal-title":"Reumatol Clin (Engl Ed)."},{"key":"10.1016\/j.medcli.2025.107076_bib0310","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.rce.2021.12.007","article-title":"Executive summary clinical practice guideline of postmenopausal, glucocortcioid-induced and male osteoporosis (2022 update). Spanish Society for Bone and Mineral Metabolism Investigation (SEIOMM)","volume":"222","author":"Riancho","year":"2022","journal-title":"Rev Clin Esp (Barc)."},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2025.107076_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract."},{"key":"10.1016\/j.medcli.2025.107076_bib0320","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.medcli.2025.107076_bib0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.medcli.2025.107076_bib0330","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.medcli.2025.107076_bib0335","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4321\/S1889-836X2021000400002","article-title":"Tratamiento secuencial en osteoporosis. Nuevas tendencias","volume":"13","author":"Casado","year":"2021","journal-title":"Rev Osteoporos Metab Miner."},{"key":"10.1016\/j.medcli.2025.107076_bib0340","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/BOR.0000000000000509","article-title":"Long-term treatment strategies for postmenopausal osteoporosis","volume":"30","author":"Cosman","year":"2018","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.medcli.2025.107076_bib0345","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","article-title":"Management of patients at very high risk of osteoporotic fractures through sequential treatments","volume":"34","author":"Curtis","year":"2022","journal-title":"Aging Clin Exp Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0350","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/17455057.3.2.243","article-title":"Anabolic therapy for osteoporosis","volume":"3","author":"Bilezikian","year":"2007","journal-title":"Womens Health (Lond)."},{"key":"10.1016\/j.medcli.2025.107076_bib0355","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107076_bib0360","doi-asserted-by":"crossref","first-page":"833221","DOI":"10.3389\/fendo.2021.833221","article-title":"PTH1R actions on bone using the cAMP\/protein kinase A pathway","volume":"12","author":"Martin","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.medcli.2025.107076_bib0365","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.tem.2019.07.014","article-title":"Handling parathormone receptor type1 in skeletal diseases: Realities and expectations of abaloparatide","volume":"30","author":"Ardura","year":"2019","journal-title":"Trends Endocrinol Metab."},{"key":"10.1016\/j.medcli.2025.107076_bib0370","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/pr.114.009464","article-title":"International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors\u2014family B G protein-coupled receptors","volume":"67","author":"Gardella","year":"2015","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.medcli.2025.107076_bib0375","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.medcli.2025.107076_bib0380","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107076_bib0385","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.medcli.2025.107076_bib0390","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev."},{"key":"10.1016\/j.medcli.2025.107076_bib0395","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.medcli.2025.107076_bib0400","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2025.107076_bib0405","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bone.2006.09.008","article-title":"Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure","volume":"40","author":"Compston","year":"2007","journal-title":"Bone."},{"key":"10.1016\/j.medcli.2025.107076_bib0410","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0415","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1210\/jc.2004-2489","article-title":"Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: New results from the fracture prevention trial","volume":"90","author":"Paschalis","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.medcli.2025.107076_bib0420","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","article-title":"Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis","volume":"18","author":"Zanchetta","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0425","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00198-018-4624-4","article-title":"Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling","volume":"29","author":"Winzenrieth","year":"2018","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.medcli.2025.107076_bib0430","doi-asserted-by":"crossref","first-page":"174409","DOI":"10.1016\/j.ejphar.2021.174409","article-title":"Abaloparatide: A review of preclinical and clinical studies","volume":"909","author":"Brent","year":"2021","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.medcli.2025.107076_bib0435","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1080\/03007995.2020.1824897","article-title":"Abaloparatide: An anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis","volume":"36","author":"Miller","year":"2020","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.medcli.2025.107076_bib0440","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.3003","article-title":"One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption","volume":"32","author":"Varela","year":"2017","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0445","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","article-title":"Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial","volume":"29","author":"Bilezikian","year":"2018","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.medcli.2025.107076_bib0450","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jbmr.4764","article-title":"Effect of abaloparatide on bone microarchitecture assessed by trabecular bone score in women with osteoporosis: Post hoc analysis of ACTIVE and ACTIVExtend","volume":"38","author":"Cosman","year":"2023","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0455","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00198-020-05806-1","article-title":"Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling","volume":"32","author":"Winzenrieth","year":"2021","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.medcli.2025.107076_bib0460","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0465","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): A multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2025.107076_bib0470","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: The VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0475","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","article-title":"Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)","volume":"85","author":"Langdahl","year":"2009","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.medcli.2025.107076_bib0480","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis","volume":"120","author":"D\u00edez-P\u00e9rez","year":"2019","journal-title":"Bone."},{"key":"10.1016\/j.medcli.2025.107076_bib0490","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.medcli.2025.107076_bib0495","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jbmr.2991","article-title":"Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0500","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/GME.0000000000001593","article-title":"Abaloparatide followed by alendronate in women \u226580years with osteoporosis: Post hoc analysis of ACTIVExtend","volume":"27","author":"Greenspan","year":"2020","journal-title":"Menopause."},{"key":"10.1016\/j.medcli.2025.107076_bib0505","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/jbmr.3848","article-title":"Fracture and bone mineral density response by baseline risk in patients treated with abaloparatide followed by alendronate: Results from the phase3 ACTIVExtend trial","volume":"34","author":"Leder","year":"2019","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0510","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/jbmr.3163","article-title":"The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: A post hoc analysis of the ACTIVE study","volume":"32","author":"McCloskey","year":"2017","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2025.107076_bib0515","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000001080","article-title":"Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis","volume":"25","author":"McClung","year":"2018","journal-title":"Menopause."},{"key":"10.1016\/j.medcli.2025.107076_bib0520","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1210\/clinem\/dgz162","article-title":"Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis","volume":"105","author":"Leder","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.medcli.2025.107076_bib0525","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","article-title":"Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.medcli.2025.107076_bib0530","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol."},{"key":"10.1016\/j.medcli.2025.107076_bib0535","doi-asserted-by":"crossref","first-page":"e10665","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus."},{"key":"10.1016\/j.medcli.2025.107076_bib0540","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type1 receptor agonist abaloparatide or PTH(1-34)","volume":"86","author":"Jolette","year":"2017","journal-title":"Regul Toxicol Pharmacol."},{"key":"10.1016\/j.medcli.2025.107076_bib0545","unstructured":"\u00abFDA approves removal of boxed warning from label for osteoporosis drug Tymlos.\u00bb Drug Discovery & Development [consultado 18 May 2025]. Disponible en: https:\/\/www.drugdiscoverytrends.com\/fda-approves-removal-of-boxed-warning-from-label-for-osteoporosis-drug-tymlos\/"},{"key":"10.1016\/j.medcli.2025.107076_bib0550","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325003045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325003045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:48:57Z","timestamp":1759999737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325003045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0025775325003045"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107076","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Los an\u00e1logos de la PTH\/PTHrP como tratamiento osteoanab\u00f3lico de los pacientes con osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"107076"}}